Transmembrane signalling systems in the brain of patients with Parkinson's disease - PubMed (original) (raw)
Review
Transmembrane signalling systems in the brain of patients with Parkinson's disease
N Nishino et al. Rev Neurosci. 1993 Apr-Jun.
Abstract
The clinical efficacy of dopamine (DA) replacement therapy for patients with Parkinson's disease (PD) depends on the preservation of postsynaptic DA receptors and their intracellular signalling mechanisms in the striatum long after degeneration of the nigrostriatal DA pathway. DA activates adenylyl cyclase (AC) and phospholipase C (PLC) via the D1 receptor, and inhibits through the D2 receptor, thereby regulating the production of intracellular second messengers, cyclic adenosine 3',5'-monophosphate (cAMP), 1,2-diacylglycerol (DAG) and Ca2+. Recent advances in molecular biology have made it possible to monitor the intracellular signal transduction cascade following receptor activation by various transmitters. The authors review the literature addressing this issue, summarized as follows: (1) striatal D1 and D2 receptor densities remain constant, at least in treated and non-demented patients; (2) DA-sensitive AC activity appears to be increased in the putamen of treated patients, although this remains to be confirmed; (3) levels of cAMP-dependent protein kinase (PKA) are normal in non-demented patients, consistent with unchanged levels of DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of M(r) 32,000); (4) levels of Ca2+/phospholipid-dependent protein kinase (PKC) and of inositol 1,4,5-trisphosphate (InsP3) receptor also remain unchanged in non-demented patients; (5) the above three second messenger sites as well as densities of D1 and D2 receptors are decreased in the striatum of demented PD patients (PDD). We tentatively conclude that postreceptor signalling function is intact in the striatum of non-demented PD patients and that there is a clear difference between non-demented patients and PDD, i.e. striatal dopaminoceptive neurons are affected in PDD.
Similar articles
- Dopamine D-1 receptor and cyclic AMP-dependent phosphorylation in Parkinson's disease.
Cash R, Raisman R, Ploska A, Agid Y. Cash R, et al. J Neurochem. 1987 Oct;49(4):1075-83. doi: 10.1111/j.1471-4159.1987.tb09996.x. J Neurochem. 1987. PMID: 2887632 - Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32.
Dunah AW, Sirianni AC, Fienberg AA, Bastia E, Schwarzschild MA, Standaert DG. Dunah AW, et al. Mol Pharmacol. 2004 Jan;65(1):121-9. doi: 10.1124/mol.65.1.121. Mol Pharmacol. 2004. PMID: 14722243 - Development of D1 and D2 dopamine receptors and associated second messenger systems in fetal striatal transplants.
Helm GA, Robertson MW, Jallo GI, Simmons N, Bennett JP Jr. Helm GA, et al. Exp Neurol. 1991 Feb;111(2):181-9. doi: 10.1016/0014-4886(91)90005-w. Exp Neurol. 1991. PMID: 1703498 - Dopamine receptors in Parkinson's disease.
Hassan MN, Thakar JH. Hassan MN, et al. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(2-3):173-82. doi: 10.1016/0278-5846(88)90035-8. Prog Neuropsychopharmacol Biol Psychiatry. 1988. PMID: 3290993 Review. - Neostriatal mechanisms in Parkinson's disease.
Chase TN, Oh JD, Blanchet PJ. Chase TN, et al. Neurology. 1998 Aug;51(2 Suppl 2):S30-5. doi: 10.1212/wnl.51.2_suppl_2.s30. Neurology. 1998. PMID: 9711978 Review.
Cited by
- Metabolomics comparison of metabolites and functional pathways in the SH-SY5Y cell model of Parkinson's disease under PEMF exposure.
Zhu LN, Chen D, He C. Zhu LN, et al. Heliyon. 2024 Feb 16;10(4):e26540. doi: 10.1016/j.heliyon.2024.e26540. eCollection 2024 Feb 29. Heliyon. 2024. PMID: 38404789 Free PMC article. - Targeting Striatal Glutamate and Phosphodiesterases to Control L-DOPA-Induced Dyskinesia.
Kochoian BA, Bure C, Papa SM. Kochoian BA, et al. Cells. 2023 Nov 30;12(23):2754. doi: 10.3390/cells12232754. Cells. 2023. PMID: 38067182 Free PMC article. Review. - An insight into reactivity and bioactivity properties of quorum sensing peptides against PDE10A: a computational peptidology approach.
Shreevatsa B, Dharmashekara C, Jain AS, Amachawadi R, Achar RR, Syed A, Shivamallu C, Kollur SP, Frau J, Flores-Holguín N, Glossman-Mitnik D. Shreevatsa B, et al. J Mol Model. 2022 Jul 5;28(8):209. doi: 10.1007/s00894-022-05176-x. J Mol Model. 2022. PMID: 35789297 - The Emerging Role of Phosphodiesterases in Movement Disorders.
Erro R, Mencacci NE, Bhatia KP. Erro R, et al. Mov Disord. 2021 Oct;36(10):2225-2243. doi: 10.1002/mds.28686. Epub 2021 Jun 21. Mov Disord. 2021. PMID: 34155691 Free PMC article. Review. - Striatal Gαolf/cAMP Signal-Dependent Mechanism to Generate Levodopa-Induced Dyskinesia in Parkinson's Disease.
Goto S. Goto S. Front Cell Neurosci. 2017 Nov 21;11:364. doi: 10.3389/fncel.2017.00364. eCollection 2017. Front Cell Neurosci. 2017. PMID: 29201000 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous